# Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Source: https://onco.cc/trials/nct05620134/  
OnCo record `nct05620134` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JK08, Pembrolizumab in metastatic cancer and melanoma, run by Salubris Biotherapeutics Inc, active and no longer recruiting.

## Summary

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05620134 by Salubris Biotherapeutics Inc, with 263 participants planned, started 2022-10-17 and due to reach its primary completion in 2025-10-17. Interventions recorded: JK08, Pembrolizumab, Lenvatinib Pill. Conditions listed: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05620134
- Phase: 1/2
- Setting: A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients with Unresectable Locally Advanced or Metastatic Cancer
- Sponsor: Salubris Biotherapeutics Inc
- Enrolled: 263

## Sources

- ClinicalTrials.gov NCT05620134: https://clinicaltrials.gov/study/NCT05620134

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [JK08](https://onco.cc/drugs/jk08/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05620134.json